Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ELX/TEZ/IVA Expanded Access Program for Patients 6 Through 11 Years of Age With Cystic Fibrosis Who Have At Least One F508del Mutation

NCT04702360 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.

NCT NCT04702360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04702360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ELX/TEZ/IVA Expanded Access Program for Patients 6 Through 11 Years of Age With Cystic Fibrosis Who Have At Least One F508del Mutation
Lead sponsor
Vertex Pharmaceuticals Incorporated
Phase
Expanded access
Overall status
Approved for marketing
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis